Myozyme (Alglucosidase Alfa)

Alglucosidase alfa, the active ingredient in Myozyme, is an enzyme replacement therapy presented as a 5 mg/mL lyophilized powder for injection for intravenous use. It provides recombinant human acid alpha‑glucosidase to patients with Pompe disease, addressing both infantile‑onset and late‑onset forms of the glycogen storage disorder.

GNH USA supplies Myozyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance. The company adheres to stringent cold‑chain logistics and provides technical support for infusion preparation.

Myozyme is used in the management of Pompe disease, a lysosomal storage disorder characterized by deficient acid alpha‑glucosidase activity. - Infantile‑onset Pompe disease: improves survival, cardiac function and motor development. - Late‑onset Pompe disease: stabilizes or improves respiratory muscle strength and walking ability. - Glycogen storage disease type II: reduces lysosomal glycogen accumulation in muscle tissue.

Myozyme may be associated with a range of adverse reactions observed during clinical use. Common Side Effects: - Infusion‑related reactions: flushing, rash, or mild fever. - Respiratory symptoms: cough or wheezing. - Gastrointestinal disturbances: nausea, vomiting or abdominal pain. - Musculoskeletal complaints: joint pain or muscle aches. Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Cardiac arrhythmias or myocardial infarction. - Renal impairment or acute kidney injury.

Prior to initiating Myozyme therapy, several precautionary measures should be considered to ensure patient safety. - Baseline assessment: evaluate cardiac, respiratory and renal function before treatment. - Infusion monitoring: observe patients closely during and after infusion for signs of hypersensitivity. - Antibody testing: consider screening for pre‑existing anti‑enzyme antibodies that may affect efficacy. - Concomitant medications: review use of immunosuppressants or antihistamines that could mask reactions. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Myozyme can interact with other medicines, affecting its safety or efficacy. Major Interactions (Avoid): - Live vaccines: concurrent administration may increase risk of infection due to immune modulation. - High‑dose immunosuppressants: may blunt therapeutic response and increase infection risk. Moderate Interactions (Monitor Closely): - Antihistamines: may mask early infusion‑related reactions, requiring careful monitoring. - ACE inhibitors or ARBs: may exacerbate renal effects, necessitating renal function checks. - Concomitant enzyme therapies: overlapping mechanisms may increase risk of adverse events.